Abstract:

The early clinical symptoms of ovarian cancer are not obvious, and most of the patients have been at the advanced stage when they were diagnosed. About 75% of patients have the peritoneal metastases of ovarian cancer which are difficult to be resected completely by surgery. The therapeutic effect of metastasizing neoplasms is poor, and neoplasm is prone to recur. The mortality rate is the first of all gynecological malignancies. Patients with the advanced ovarian cancer and the peritoneal metastasis are often accompanied by different degrees of cancerous peritoneal effusion, and the main treatment goal is to control local development. Therefore, cytoreductive surgery and intraperitoneal injection of chemotherapy drugs are of important treatment methods for those patients with peritoneal metastasis of ovarian cancer. Compared with the conventional intravenous chemotherapy, intraperitoneal chemotherapy methods such as hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) have outstanding advantages in reducing tumor volume and controlling malignant peritoneal effusion, which can significantly prolong recurrence-free survival (RFS), disease-free survival (DFS) and overall survival (OS) of patients. Meanwhile, the intraperitoneal chemotherapy methods reduce treatment-related adverse reactions, and improve life quality of patients. This paper reviews the intraperitoneal chemotherapy methods of the peritoneal metastases of ovarian cancer and the research progress, in order to provide a reference for clinical treatment.

Key words: Ovarian neoplasms, Peritoneal neoplasms, Neoplasm metastases, Injections,intraperitoneal, Drug therapy